S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Safest Option in Trades! (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
How Much Longer Will It Be Under $1? (Ad)pixel
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
How Much Longer Will It Be Under $1? (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Safest Option in Trades! (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
How Much Longer Will It Be Under $1? (Ad)pixel
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
How Much Longer Will It Be Under $1? (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Safest Option in Trades! (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
How Much Longer Will It Be Under $1? (Ad)pixel
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
How Much Longer Will It Be Under $1? (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The Safest Option in Trades! (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Italy's Lake Garda shrinks to near-historic low amid drought
How Much Longer Will It Be Under $1? (Ad)pixel
Germans urged to cap heat in offices this winter to save gas
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
How Much Longer Will It Be Under $1? (Ad)pixel
NASDAQ:DMTK

DermTech - DMTK Stock Forecast, Price & News

$6.80
+0.53 (+8.45%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$6.38
$6.82
50-Day Range
$4.39
$8.68
52-Week Range
$4.18
$38.97
Volume
772,561 shs
Average Volume
983,405 shs
Market Capitalization
$204.27 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$24.17

DermTech MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
255.4% Upside
$24.17 Price Target
Short Interest
Bearish
15.32% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.09mentions of DermTech in the last 14 days
Based on 24 Articles This Week
Insider Trading
Selling Shares
$23,470 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.08) to ($4.02) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.97 out of 5 stars

Medical Sector

812th out of 1,135 stocks

Medical Laboratories Industry

21st out of 28 stocks

DMTK stock logo

About DermTech (NASDAQ:DMTK) Stock

DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.

DermTech Stock Performance

DMTK opened at $6.80 on Friday. The stock has a market cap of $204.27 million, a price-to-earnings ratio of -1.91 and a beta of 1.40. The stock's 50 day moving average price is $6.44 and its 200-day moving average price is $9.55. DermTech has a one year low of $4.18 and a one year high of $38.97.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on DMTK. BTIG Research reduced their price objective on DermTech from $38.00 to $19.00 and set a "buy" rating on the stock in a research note on Tuesday, June 14th. Cowen reduced their price objective on DermTech from $33.00 to $20.00 in a research note on Wednesday, May 4th. Lake Street Capital reduced their price objective on DermTech from $34.00 to $14.00 in a research note on Tuesday, August 9th. Oppenheimer reissued an "outperform" rating and set a $48.00 price objective on shares of DermTech in a research note on Monday, July 18th. Finally, Craig Hallum reduced their price objective on DermTech from $37.00 to $18.00 in a research note on Tuesday, August 9th.

Receive DMTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DermTech and its competitors with MarketBeat's FREE daily newsletter.

DMTK Stock News Headlines

DermTech (NASDAQ:DMTK) PT Lowered to $14.00
DermTech: Q2 Earnings Insights - Benzinga
DermTech (DMTK) to Release Earnings on Monday
DermTech's (DMTK) Outperform Rating Reiterated at Oppenheimer
DermTech Appoints Two New Board Members
See More Headlines
Receive DMTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DermTech and its competitors with MarketBeat's FREE daily newsletter.

DMTK Company Calendar

Last Earnings
11/09/2021
Today
8/14/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DMTK
Fax
N/A
Employees
255
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$24.17
High Stock Price Forecast
$48.00
Low Stock Price Forecast
$14.00
Forecasted Upside/Downside
+255.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-78,330,000.00
Net Margins
-748.29%
Pretax Margin
-748.29%

Debt

Sales & Book Value

Annual Sales
$11.84 million
Book Value
$5.94 per share

Miscellaneous

Free Float
28,959,000
Market Cap
$204.27 million
Optionable
Not Optionable
Beta
1.40

Key Executives














DMTK Stock - Frequently Asked Questions

Should I buy or sell DermTech stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DermTech in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DMTK shares.
View DMTK analyst ratings
or view top-rated stocks.

What is DermTech's stock price forecast for 2022?

4 Wall Street analysts have issued twelve-month price targets for DermTech's shares. Their DMTK share price forecasts range from $14.00 to $48.00. On average, they expect the company's stock price to reach $24.17 in the next twelve months. This suggests a possible upside of 255.4% from the stock's current price.
View analysts price targets for DMTK
or view top-rated stocks among Wall Street analysts.

How have DMTK shares performed in 2022?

DermTech's stock was trading at $15.80 at the start of the year. Since then, DMTK stock has decreased by 57.0% and is now trading at $6.80.
View the best growth stocks for 2022 here
.

When is DermTech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our DMTK earnings forecast
.

How were DermTech's earnings last quarter?

DermTech, Inc. (NASDAQ:DMTK) announced its earnings results on Tuesday, November, 9th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.65) by $0.03. The business had revenue of $3.03 million for the quarter, compared to analyst estimates of $3.40 million. DermTech had a negative net margin of 748.29% and a negative trailing twelve-month return on equity of 49.02%. During the same quarter in the prior year, the company earned ($0.50) earnings per share.

What other stocks do shareholders of DermTech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DermTech investors own include Pfizer (PFE), CrowdStrike (CRWD), DocuSign (DOCU), ONEOK (OKE), Intel (INTC), U.S. Xpress Enterprises (USX), Valero Energy (VLO), Hello Group (MOMO), AVEO Pharmaceuticals (AVEO) and Camping World (CWH).

What is DermTech's stock symbol?

DermTech trades on the NASDAQ under the ticker symbol "DMTK."

Who are DermTech's major shareholders?

DermTech's stock is owned by many different retail and institutional investors. Top institutional shareholders include Victory Capital Management Inc. (3.65%), AEGON ASSET MANAGEMENT UK Plc (1.64%), Landscape Capital Management L.L.C. (1.36%), Epiq Partners LLC (0.67%), King Luther Capital Management Corp (0.65%) and Oak Ridge Investments LLC (0.48%). Insiders that own company stock include Burkhard Jansen, Claudia Ibarra, Enrico Picozza, Herm Rosenman, John Dobak, Kevin M Sun, Kevin M Sun, Matthew L Posard, Mutual Insurance Co Donegal, Rtw Investments, Lp, Scott R Pancoast and Todd Michael Wood.
View institutional ownership trends
.

How do I buy shares of DermTech?

Shares of DMTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DermTech's stock price today?

One share of DMTK stock can currently be purchased for approximately $6.80.

How much money does DermTech make?

DermTech (NASDAQ:DMTK) has a market capitalization of $204.27 million and generates $11.84 million in revenue each year. The company earns $-78,330,000.00 in net income (profit) each year or ($3.56) on an earnings per share basis.

How many employees does DermTech have?

The company employs 255 workers across the globe.

How can I contact DermTech?

DermTech's mailing address is 11099 N. Torrey Pines Road Suite 100, La Jolla CA, 92037. The official website for the company is www.dermtech.com. The company can be reached via phone at (858) 450-4222 or via email at investorrelations@dermtech.com.

This page (NASDAQ:DMTK) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.